Apogee buy delivers eczema trial win for AbbVie
Apogee buy delivers eczema trial win for AbbVie
AbbVie
AbbVie (NYSE: ABBV) is a global, research-driven biopharmaceutical company formed in 2013 following its separation from Abbott Laboratories. AbbVie develops and commercializes therapeutics across immunology (Humira, Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta, Epkinly), neuroscience (Vraylar, Duopa), and aesthetics (Botox, Juvederm), with growing investments in oncology, neuroscience, and eye care.
Company Info
Sector:Diversified Biopharmaceuticals
Headquarters:North Chicago, Illinois, USA
Founded:2013
Website:www.abbvie.com/
Recent News
AbbVie wins FDA approval for Parkinson's drug from $8.7B Cerevel takeover
AbbVie wins FDA approval for Parkinson's drug from $8.7B Cerevel takeover
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
AbbVie's JUVMO (tavapadon) is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. The once-daily tablet works with or without levodopa, and the approval is supported by the Phase 3 TEMPO programme.
AbbVie eyes Qulipta expansion after menstrual migraine win
AbbVie eyes Qulipta expansion after menstrual migraine win — latest pharmaceutical industry news.
AbbVie bispecific shows promise in ph. 3 multiple myeloma trial
AbbVie bispecific shows promise in ph. 3 multiple myeloma trial
AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study
Article from BioSpace about AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study.
AbbVie taps '26 cohort of immunology scholarship recipients
AbbVie taps '26 cohort of immunology scholarship recipients
Skyrizi's momentum defies J&J's rival Icotyde as AbbVie raises full-year sales guidance
AbbVie raised its full-year sales guidance on the strength of Skyrizi, whose momentum is holding up against Johnson & Johnson's rival drug Icotyde.
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
Pfizer plots Litfulo vitiligo filings, pressuring Incyte, AbbVie
Pfizer plots Litfulo vitiligo filings, pressuring Incyte, AbbVie
Amgen, AbbVie say IRA negotiations impacted Q1 sales
Amgen, AbbVie say IRA negotiations impacted Q1 sales — Endpoints News coverage of biopharma industry developments.
AbbVie and Genmab's latest win brings Epkinly closer to label expansion
AbbVie and Genmab's latest win brings Epkinly closer to label expansion — Endpoints News coverage of biopharma industry developments.
AbbVie, Genmab's Epkinly redeems itself in DLBCL
Epkinly (epcoritamab), the AbbVie/Genmab bispecific antibody, showed a significant progression-free survival benefit in combination with rituximab and lenalidomide for relapsed/refractory DLBCL in a Phase 3 trial.
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
AbbVie scooped up immunology player Apogee Therapeutics for nearly $11 billion in one of the year’s top deals to-date, while Sanofi made a big play to survive its upcoming Dupixent patent cliff; FDA uncertainty continues as the agency changes direction on gene therapies by uniQure and REGENXBIO;…
AbbVie inks $10.9B Apogee buyout to bag eczema prospect
Fierce Biotech reports AbbVie is acquiring Apogee Therapeutics for $10.9B to gain control of a late-phase eczema drug candidate that could compete with Lilly, Regeneron, and Sanofi.
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie announced a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, deepening its immunology pipeline with clinical-stage candidates including APG777 (anti-IL-13) for atopic dermatitis.
AbbVie sharpens immunology focus with $10.9 billion Apogee deal
AbbVie sharpens immunology focus with $10.9 billion Apogee deal. (Reuters Biopharma.)
Leadership Team
Robert A. Michael
Chairman and Chief Executive Officer